Motoki Tagami
Overview
Explore the profile of Motoki Tagami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamagata K, Uzu E, Yoshigai Y, Kato C, Tagami M
Eur J Pharmacol
. 2021 May;
903:174116.
PMID: 33957086
Inhibition of programmed death-ligand 1 (PD-L1) in cancer cells provides a reasonable avenue to prevent cancer progression. Although oleate is known to exert anti-cancer effects, its PD-L1 inhibitory effects have...
2.
Yamagata K, Hashiguchi K, Yamamoto H, Tagami M
J Cardiovasc Pharmacol
. 2019 Dec;
74(6):558-565.
PMID: 31815868
By inducing vascular inflammation, trimethylamine-N-oxide (TMAO) is associated with endothelial dysfunction, atherosclerosis, and enhanced risk of cardiovascular diseases in humans. However, the underlying mechanisms are unknown. Expression of several genes...
3.
Yamagata K, Izawa Y, Onodera D, Tagami M
Mol Cell Biochem
. 2017 Sep;
441(1-2):9-19.
PMID: 28875417
Previous studies indicated that chlorogenic acid, a compound present in many fruits and vegetables, has anti-cancer activities. We report that chlorogenic acid regulates the expression of apoptosis-related genes and self-renewal-related...
4.
Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, et al.
Lipids Health Dis
. 2017 Jun;
16(1):122.
PMID: 28646901
Background: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with...
5.
Yamagata K, Suzuki S, Tagami M
Prostaglandins Leukot Essent Fatty Acids
. 2016 Jan;
104:11-8.
PMID: 26802937
We investigated how docosahexaenoic acid (DHA) regulated tumor necrosis factor-alpha (TNF-α)-induced senescence and dysfunction in endothelial cells (EC). We used RT-PCR to examine the expression of several genes related to...
6.
Sakamoto K, Kawamura M, Kohro T, Omura M, Watanabe T, Ashidate K, et al.
PLoS One
. 2015 Sep;
10(9):e0138332.
PMID: 26398887
Background: There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on...
7.
Yamagata K, Xie Y, Suzuki S, Tagami M
Phytomedicine
. 2015 May;
22(4):431-7.
PMID: 25925964
Tumor necrosis factor alpha (TNF-α) promotes the expression of adhesion molecules and induces endothelial dysfunction, a process that can lead to atherosclerosis. Green tea consumption can inhibit endothelial dysfunction and...
8.
Yamagata K, Tagami M, Yamori Y
Nutrition
. 2014 Dec;
31(1):28-37.
PMID: 25466651
Vascular endothelial cell (EC) dysfunction strongly induces development of cardiovascular and cerebrovascular diseases. Epidemiologic studies demonstrated a preventative effect of dietary polyphenols toward cardiovascular disease. In studies using cultured vascular...
9.
Yamagata K, Tusruta C, Ohtuski A, Tagami M
Prostaglandins Leukot Essent Fatty Acids
. 2014 Feb;
90(4):125-32.
PMID: 24518001
Docosahexaenoic acid (DHA) prevents atherosclerosis and may decrease monocyte/macrophage activation by tumor necrosis factor (TNF)-α. Here, we sought to determine the protective effects of DHA against TNF-α-induced stimulation of lectin-like...
10.
Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, et al.
Lipids Health Dis
. 2013 Oct;
12:142.
PMID: 24094079
Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins...